|
|
|
Browse online courses created through SITC's collaborative partnerships.
|
 | Access Course
 Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface. Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.
This activity is intended for hematologist/oncologist specialists.
The goal of this activity is to provide clinicians with the latest data, concepts, and recommendations regarding the diagnosis, biomarker testing, evidence-based frontline treatment, and potential treatment-related adverse events of patients with advanced lung cancer.
Learning Objectives:
- Select appropriate diagnostic and biomarker tests to guide treatment selection for a patient with advanced lung cancer.
- Order an appropriate, evidence-based frontline treatment regimen for a patient with advanced lung cancer.
- Provide patient education for potential treatment-related adverse events.
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 18, 2020 - Mar. 18, 2021
Developed through a partnership between SITC and Medscape.
Additional Lung Cancer Resources for Clinicans from SITC:
 "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)
View Guidelines Here.
View On-demand Webinar Here.
| | Original Course Date: March 19, 2020
|
Approved Credit: : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
| MORE INFO |
| Access Course
 Experts discuss the use of checkpoint inhibition in metastatic melanoma as well as its expansion into the adjuvant setting and beyond.
This activity is intended for oncologists, dermatologists, and other healthcare professionals who treat patients with melanoma.
The goal of this activity is to increase understanding of the latest advances in the use of immunotherapy for the treatment of melanoma.
Learning Objectives:
- Have increased knowledge regarding the emerging clinical trials data on the use of immune-modulating agents in the management of melanoma
- Have increased knowledge regarding the place in therapy for immune checkpoint inhibitors in patients with melanoma
Approximate Time to Complete: 30 minutes
Credit Available: Mar. 4, 2020 - Mar. 4, 2021
Developed through a partnership between SITC and Medscape.
Additional Melanoma Resources for Clinicans from SITC:
"The Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma" (Published May 30, 2018)
View Guidelines Here.
View On-demand Webinar Here.
| | Original Course Date: March 04, 2020
|
Approved Credit: : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 CreditACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| | MORE INFO |
| Access Course
 Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019- Apr. 30, 2020
Developed through a partnership between SITC and Medscape.
| | Original Course Date: April 30, 2019
|
Approved Credit: ABIM: 0.50 hours ABIM MOC Part 2 CreditsACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
| | MORE INFO |
| Access Course
 Nursing experts discuss the emergence of immunotherapy in GI cancers, focusing on the role of biomarkers and the management of irAEs.
This activity is intended for nurses and other healthcare professionals who manage patients with gastrointestinal cancers.
The goal of this activity is to discuss the emerging role of immunotherapy using immune checkpoint inhibitors in patients with gastrointestinal cancers.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019 - Apr. 30, 2020
Developed through a partnership between SITC and Medscape.
| | Original Course Date: April 30, 2019
|
Approved Credit: ANCC: 0.50 hours Contact Hour
| | MORE INFO |
| Access Course
 This article is for people who have advanced bladder cancer or anyone who wants to learn more about advanced bladder cancer. The goal of this patient education activity is to make patients more aware of available treatment options for advanced bladder cancer.
You will learn about:
- What chemotherapy is and how it is used to treat advanced bladder cancer
- What checkpoint inhibitors are and how they are used to treat advanced bladder cancer
- The potential side effects of chemotherapy and checkpoint inhibitors
- Why the side effects from chemotherapy and checkpoint inhibitors are different
- Questions to ask your doctor
Available beginning: April 26, 2019
Approximate Time to Complete: 30 minutes
Developed through a partnership between SITC and Medscape.
| | Original Course Date: April 26, 2019
| | MORE INFO |
| Access Course
 Explore the latest in melanoma care through 2 cases, one in the adjuvant setting and one in the metastatic setting.
This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with melanoma.
Credit Available: Feb. 25, 2019 - Feb. 25, 2020
Approximate Time to Complete: 75 minutes
Developed through a partnership between SITC and Medscape.
| | Original Course Date: February 25, 2019
| | MORE INFO |
|
|
